Esperion Therapeutics (ESPR) Misses Q1 EPS by 5c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.21), $0.05 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $64.99 million versus the consensus estimate of $50.64 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Klarna (KLAR) Reiterated at Market Perform by Citizens Amid Volume Headwinds
• Hovnanian Enterprises (HOV) Reiterated at Market Underperform by Citizens as Orders Rise
• JPMorgan Upgrades TIC Solutions (TIC) to Neutral